Spots Global Cancer Trial Database for medi4736
Every month we try and update this database with for medi4736 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Phase 1b/2 Study of MEDI4736 With Tremelimumab, MEDI4736 or Tremelimumab Monotherapy in Gastric or GEJ Adenocarcinoma | NCT02340975 | Gastric or Gast... | MEDI4736 + trem... MEDI4736 + trem... MEDI4736 Tremelimumab MEDI4736+tremel... MEDI4736 + trem... | 18 Years - 99 Years | MedImmune LLC | |
| Phase III Study to Determine Efficacy of Durvalumab in Stage II-III Non-small Cell Lung Cancer (NSCLC) After Curative Intent Therapy. | NCT04642469 | Carcinoma, Non-... | Durvalumab Placebo | 18 Years - 130 Years | AstraZeneca | |
| An Efficacy and Safety Study of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Adults With Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly Patients With Acute Myeloid Leukemia (AML) | NCT02775903 | Leukemia, Myelo... Myelodysplastic... | Azacitidine Durvalumab | 18 Years - | Celgene | |
| SCION: SABR and Checkpoint Inhibition Of NSCLC | NCT04944173 | Non Small Cell ... Carcinoma, Non-... Non-small Cell ... Lung Cancer Lung Cancer Sta... Lung Adenocarci... Lung Squamous C... | Durvalumab Stereotactic Bo... Circulating Tum... | 18 Years - | University of British Columbia | |
| Pilot Study of Durvalumab and Vigil in Advanced Women's Cancers | NCT02725489 | Breast Cancer Ovarian Cancer Fallopian Tube ... Primary Periton... Uterine Cancer Cervical Cancer Endometrial Can... | Vigil Durvalumab | 18 Years - | Mary Crowley Medical Research Center | |
| A Global Study to Assess the Effects of MEDI4736 (Durvalumab) in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer | NCT02087423 | Non-Small Cell ... | MEDI4736 | 18 Years - 130 Years | AstraZeneca | |
| MEDI4736 With Selumetinib for KRAS Mutant Non-Small Cell Lung Cancer (NSCLC) | NCT03004105 | Malignant Neopl... Advanced Lung C... Recurrent Nonsm... | Selumetinib Durvalumab Phone Calls | 18 Years - | M.D. Anderson Cancer Center | |
| A Study of Durvalumab or Tremelimumab Monotherapy, or Durvalumab in Combination With Tremelimumab or Bevacizumab in Advanced Hepatocellular Carcinoma | NCT02519348 | Hepatocellular ... | Tremelimumab Durvalumab Bevacizumab | 18 Years - 99 Years | MedImmune LLC | |
| A Study of Durvalumab as Consolidation Therapy in Non-Small Cell Lung Cancer Patients | NCT03706690 | Carcinoma, Non-... | Durvalumab Placebo | 18 Years - 130 Years | AstraZeneca | |
| Addition of PD-L1 Antibody MEDI4736 to a Taxane-anthracycline Chemotherapy in Triple Negative Breast Cancer | NCT02685059 | Breast Cancer | MEDI4736 (Anti ... Placebo nab-Paclitaxel Epirubicin Cyclophosphamid... | 18 Years - | German Breast Group | |
| Study of MEDI4736 Monotherapy and in Combination With Tremelimumab Versus Standard of Care Therapy in Patients With Head and Neck Cancer | NCT02369874 | Recurrent or Me... | MEDI4736 MEDI4736 + Trem... Standard of Car... | 18 Years - 96 Years | AstraZeneca | |
| Durvalumab And Radiation Therapy Followed by Adjuvant Durvalumab in Patients With Urothelial Cancer (T2-4 N0-2 M0) of the Bladder | NCT02891161 | Urothelial Canc... | durvalumab Radiation Thera... | 18 Years - | Big Ten Cancer Research Consortium | |
| A Study of MEDI1191 in Sequential and Concurrent Combination With Durvalumab in Subjects With Advanced Solid Tumors | NCT03946800 | Solid Tumors Cancer | MEDI1191 Durvalumab | 18 Years - 101 Years | MedImmune LLC | |
| Intensified Chemo-immuno-radiotherapy With Durvalumab for Stage III Non-Small Cell Lung Cancers | NCT04230408 | Lung Neoplasms | Durvalumab | 18 Years - | Latin American Cooperative Oncology Group | |
| A Phase I Study to Evaluate the Safety, Tolerability and Efficacy of MEDI4736 (Durvalumab) With Tremelimumab in Head and Neck Cancer | NCT02262741 | Squamous Cell C... | MEDI4736 tremelimumab | 18 Years - 99 Years | MedImmune LLC | |
| Study to Evaluate the Safety and Pharmacokinetics of MEDI9090 in Subjects With Advanced Solid Tumors | NCT02900157 | Advanced Solid ... | MEDI9090 Durvalumab | 18 Years - 99 Years | MedImmune LLC | |
| Neoadjuvant MEDI4736 Concomitant With Weekly Nab-paclitaxel and Dose-dense AC for Stage I-III Triple Negative Breast Cancer | NCT02489448 | Breast Neoplasm... | MEDI4736 | 18 Years - | Yale University | |
| Phase 1/2 Study of Motolimod, Doxorubicin, and Durvalumab in Recurrent, Platinum-Resistant Ovarian Cancer | NCT02431559 | Ovarian Cancer | Durvalumab Pegylated Lipos... Motolimod | 18 Years - | Ludwig Institute for Cancer Research | |
| A Study of Durvalumab With or Without Tremelimumab in Endometrial Cancer | NCT03015129 | Endometrial Can... Endometrial Car... Endometrial Car... Endometrial Can... Endometrial Car... | Durvalumab Tremelimumab | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Lymphomas | NCT02401048 | Diffuse Large B... Follicular Lymp... | Ibrutinib MEDI4736 | 18 Years - | Pharmacyclics LLC. | |
| Safety and Efficacy Study of Nab®-Paclitaxel With CC-486 or Nab®-Paclitaxel With Durvalumab, and Nab®-Paclitaxel Monotherapy as Second/Third-line Treatment for Advanced Non-small Cell Lung Cancer | NCT02250326 | Carcinoma, Non-... | nab-paclitaxel ... CC-486 Duravalumab | 18 Years - | Celgene | |
| A Study to Determine Dose and Regimen of Durvalumab as Monotherapy or in Combination With Pomalidomide With or Without Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma | NCT02616640 | Multiple Myelom... | Durvalumab Pomalidomide Dexamethasone | 18 Years - | Celgene | |
| A Global Study to Assess the Effects of MEDI4736 (Durvalumab) in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer | NCT02087423 | Non-Small Cell ... | MEDI4736 | 18 Years - 130 Years | AstraZeneca | |
| A Study to Determine Dose, Safety, and Efficacy of Durvalumab as Monotherapy and in Combination Therapy in Subjects With Lymphoma or Chronic Lymphocytic Leukemia | NCT02733042 | Lymphoma Leukemia, Lymph... | Durvalumab Lenalidomide Rituximab Ibrutinib Bendamustine | 18 Years - | Celgene | |
| SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer | NCT02299999 | Metastatic Brea... | AZD2014 AZD4547 AZD5363 AZD8931 Selumetinib Vandetanib Bicalutamide Olaparib Anthracyclines Taxanes cyclophosphamid... DNA intercalato... Methotrexate vinca alkaloids Platinum based ... Bevacizumab Mitomycin C Eribulin MEDI4736 | 18 Years - | UNICANCER | |
| A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers | NCT02643303 | Head and Neck S... Breast Cancer Sarcoma Merkel Cell Car... Cutaneous T-Cel... Melanoma Renal Cancer Bladder Cancer Prostate Cancer Testicular Canc... Solid Tumor | Durvalumab Tremelimumab Poly-ICLC | 18 Years - | Ludwig Institute for Cancer Research | |
| Trial Of Hypofractionated Radiotherapy In Combination With MEDI4736 And Tremelimumab For Patients With Metastatic Melanoma And Lung, Breast And Pancreatic Cancers | NCT02639026 | Metastatic Melanoma Non Small Cell ... Breast Cancer Pancreatic Canc... | Radiotherapy MEDI4736 Tremelimumab | 18 Years - | Abramson Cancer Center at Penn Medicine | |
| A Phase 1 Study of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Solid Tumors | NCT02261220 | Advanced Solid ... | MEDI4736 tremelimumab | 18 Years - 99 Years | MedImmune LLC | |
| MEDI4736 (Anti PD-L1) Combined With Gefitinib in Subjects With Non-Small Cell Lung Cancer(NSCLC). | NCT02088112 | Carcinoma, Non-... | Gefitinib MEDI4736 | 18 Years - 130 Years | MedImmune LLC | |
| A Phase 1b Study of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Non-small Cell Lung Cancer | NCT02000947 | NSCLC Non-small Cell ... Lung Cancer | MEDI4736 Tremelimumab tremelimumab | 18 Years - 101 Years | MedImmune LLC | |
| Durvalumab vs Placebo With Stereotactic Body Radiation Therapy in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients / Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR Mutation | NCT03833154 | Carcinoma, Non-... | Durvalumab Placebo Osimertinib (si... | 18 Years - 130 Years | AstraZeneca | |
| A Study of Durvalumab or Tremelimumab Monotherapy, or Durvalumab in Combination With Tremelimumab or Bevacizumab in Advanced Hepatocellular Carcinoma | NCT02519348 | Hepatocellular ... | Tremelimumab Durvalumab Bevacizumab | 18 Years - 99 Years | MedImmune LLC | |
| First Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid Tumours | NCT04504669 | Clear Cell Rena... Non-Small-Cell ... Triple Negative... Squamous Cell C... Small Cell Lung... Gastroesophagea... Melanoma Cervical Cancer Advanced Solid ... | AZD8701 Durvalumab | 18 Years - 101 Years | AstraZeneca | |
| AZD9291 in Combination With Ascending Doses of Novel Therapeutics | NCT02143466 | Advanced Non Sm... | Part A - AZD929... Part A - AZD929... Part A - AZD929... Part A - AZD929... Part A - AZD929... Part B - AZD929... Part B - AZD929... Part B - AZD929... Part C - AZD609... Part C - AZD929... Part D - AZD929... | 18 Years - 130 Years | AstraZeneca | |
| A Study of Durvalumab (Anti-PDL1) Plus Radiation Therapy for the Treatment of Solitary Bone Plasmacytoma | NCT03196401 | Solitary Bone P... | Durvalumab Radiation thera... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Durvalumab vs Placebo With Stereotactic Body Radiation Therapy in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients / Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR Mutation | NCT03833154 | Carcinoma, Non-... | Durvalumab Placebo Osimertinib (si... | 18 Years - 130 Years | AstraZeneca | |
| A Study of Durvalumab as Consolidation Therapy in Non-Small Cell Lung Cancer Patients | NCT03706690 | Carcinoma, Non-... | Durvalumab Placebo | 18 Years - 130 Years | AstraZeneca | |
| Phase 2 Durvalumab (Medi4736) for Bacillus Calmette-Guérin (BCG) Refactory Urothelial Carcinoma in Situ of the Bladder | NCT02901548 | Carcinoma in Si... Bladder Cancer | Durvalumab Cystoscopy with... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| A Study of Durvalumab or Tremelimumab Monotherapy, or Durvalumab in Combination With Tremelimumab or Bevacizumab in Advanced Hepatocellular Carcinoma | NCT02519348 | Hepatocellular ... | Tremelimumab Durvalumab Bevacizumab | 18 Years - 99 Years | MedImmune LLC | |
| A Phase 1b/2 Study of MEDI4736 With Tremelimumab, MEDI4736 or Tremelimumab Monotherapy in Gastric or GEJ Adenocarcinoma | NCT02340975 | Gastric or Gast... | MEDI4736 + trem... MEDI4736 + trem... MEDI4736 Tremelimumab MEDI4736+tremel... MEDI4736 + trem... | 18 Years - 99 Years | MedImmune LLC | |
| Double Blind Placebo Controlled Controlled Study of Adjuvant MEDI4736 In Completely Resected NSCLC | NCT02273375 | Non-Small Cell ... | MEDI4736 Placebo | 18 Years - | Canadian Cancer Trials Group | |
| Phase III Open Label Study of MEDI 4736 With/Without Tremelimumab Versus Standard of Care (SOC) in Recurrent/Metastatic Head and Neck Cancer | NCT02551159 | Squamous Cell C... | MEDI4736 Tremelimumab MEDI4736+Tremel... Cetuximab 5-fluorouracil ... Cisplatin Carboplatin | 18 Years - 130 Years | AstraZeneca | |
| A Study to Determine Dose and Regimen of Durvalumab as Monotherapy or in Combination With Pomalidomide With or Without Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma | NCT02616640 | Multiple Myelom... | Durvalumab Pomalidomide Dexamethasone | 18 Years - | Celgene | |
| Trial Of Hypofractionated Radiotherapy In Combination With MEDI4736 And Tremelimumab For Patients With Metastatic Melanoma And Lung, Breast And Pancreatic Cancers | NCT02639026 | Metastatic Melanoma Non Small Cell ... Breast Cancer Pancreatic Canc... | Radiotherapy MEDI4736 Tremelimumab | 18 Years - | Abramson Cancer Center at Penn Medicine | |
| Study of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE) | NCT02542293 | Non Small Cell ... | Durvalumab +Tre... Paclitaxel + ca... Gemcitabine + c... Gemcitabine + c... Pemetrexed + ci... Pemetrexed + ca... | 18 Years - 130 Years | AstraZeneca | |
| Double Blind Placebo Controlled Controlled Study of Adjuvant MEDI4736 In Completely Resected NSCLC | NCT02273375 | Non-Small Cell ... | MEDI4736 Placebo | 18 Years - | Canadian Cancer Trials Group | |
| Assessment of Efficacy and Safety of Durvalumab Plus BCG Compared to the Standard Therapy With BCG in Non-muscle Invasive Bladder Cancer | NCT03528694 | Non-muscle-inva... | Durvalumab (MED... Bacillus Calmet... | 18 Years - 130 Years | AstraZeneca | |
| Phase 2 Study of Durvalumab (MEDI4736) in Patients With Glioblastoma | NCT02336165 | Glioblastoma | Durvalumab Standard radiot... Bevacizumab | 18 Years - | Ludwig Institute for Cancer Research | |
| Safety, Tolerability and Pharmacokinetics of AZD1775 (Adavosertib) Plus MEDI4736 (Durvalumab) in Patients With Advanced Solid Tumours | NCT02617277 | Advanced Solid ... | AZD1775 MEDI4736 | 18 Years - 130 Years | AstraZeneca | |
| Study of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE) | NCT02542293 | Non Small Cell ... | Durvalumab +Tre... Paclitaxel + ca... Gemcitabine + c... Gemcitabine + c... Pemetrexed + ci... Pemetrexed + ca... | 18 Years - 130 Years | AstraZeneca | |
| Phase III Open Label Study of MEDI 4736 With/Without Tremelimumab Versus Standard of Care (SOC) in Recurrent/Metastatic Head and Neck Cancer | NCT02551159 | Squamous Cell C... | MEDI4736 Tremelimumab MEDI4736+Tremel... Cetuximab 5-fluorouracil ... Cisplatin Carboplatin | 18 Years - 130 Years | AstraZeneca | |
| MEDI4736 Or MEDI4736 + Tremelimumab In Surgically Resectable Malignant Pleural Mesothelioma | NCT02592551 | Mesothelioma | MEDI4736 Tremelimumab no other name | 18 Years - | Baylor College of Medicine | |
| Phase II Study of MEDI4736 Monotherapy in Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck | NCT02207530 | Recurrent or Me... | MEDI4736 | 18 Years - 130 Years | AstraZeneca | |
| A Study of Durvalumab With or Without Tremelimumab in Endometrial Cancer | NCT03015129 | Endometrial Can... Endometrial Car... Endometrial Car... Endometrial Can... Endometrial Car... | Durvalumab Tremelimumab | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| A Study of Durvalumab (MEDI4736) in Esophageal Cancer | NCT02639065 | Esophageal Canc... | Durvalumab | 18 Years - | Big Ten Cancer Research Consortium | |
| Durvalumab and Tremelimumab Combination in Somatically Hypermutated Recurrent Solid Tumors | NCT03911557 | Tumor, Solid | Durvalumab and ... | 18 Years - | University of Kentucky | |
| Anti-PD-L1 in Stage IIIA(N2) Non-small Cell Lung Cancer (NSCLC) | NCT02572843 | NSCLC Non-small... | MEDI4736 (anti-... | 18 Years - 75 Years | Swiss Group for Clinical Cancer Research | |
| A Global Study to Assess the Effects of MEDI4736 Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer | NCT02125461 | Non-Small Cell ... | MEDI4736 PLACEBO | 18 Years - 130 Years | AstraZeneca | |
| Phase 1/2 Study of Motolimod, Doxorubicin, and Durvalumab in Recurrent, Platinum-Resistant Ovarian Cancer | NCT02431559 | Ovarian Cancer | Durvalumab Pegylated Lipos... Motolimod | 18 Years - | Ludwig Institute for Cancer Research | |
| An Efficacy and Safety Study of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Adults With Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly Patients With Acute Myeloid Leukemia (AML) | NCT02775903 | Leukemia, Myelo... Myelodysplastic... | Azacitidine Durvalumab | 18 Years - | Celgene | |
| Ph1 to Assess Safety, Tolerability of Tremelimumab/ Tremelimumab+MEDI4736 in Japanese Solid Malignancies/ Mesothelioma | NCT02141347 | Part A and B: A... Part C: Maligna... | Tremelimumab MEDI4736 | 20 Years - 130 Years | AstraZeneca | |
| Anti-PD-L1 in Stage IIIA(N2) Non-small Cell Lung Cancer (NSCLC) | NCT02572843 | NSCLC Non-small... | MEDI4736 (anti-... | 18 Years - 75 Years | Swiss Group for Clinical Cancer Research | |
| Pilot Study of Durvalumab and Vigil in Advanced Women's Cancers | NCT02725489 | Breast Cancer Ovarian Cancer Fallopian Tube ... Primary Periton... Uterine Cancer Cervical Cancer Endometrial Can... | Vigil Durvalumab | 18 Years - | Mary Crowley Medical Research Center | |
| MEDI4736 Alone and in Combination With Tremelimumab or AZD9150 in Adult Subjects With Relapsed/Refractory DLBCL (D4190C00023) | NCT02549651 | Diffuse Large B... | MEDI4736 tremelimumab AZD9150 | 18 Years - | MedImmune LLC | |
| Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer | NCT02546661 | Muscle Invasive... | AZD4547 MEDI4736 Olaparib AZD1775 Vistusertib AZD9150 Selumetinib | 18 Years - 130 Years | AstraZeneca | |
| A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers | NCT02643303 | Head and Neck S... Breast Cancer Sarcoma Merkel Cell Car... Cutaneous T-Cel... Melanoma Renal Cancer Bladder Cancer Prostate Cancer Testicular Canc... Solid Tumor | Durvalumab Tremelimumab Poly-ICLC | 18 Years - | Ludwig Institute for Cancer Research | |
| A Study of Epacadostat (INCB024360) in Combination With Durvalumab (MEDI4736) in Subjects With Selected Advanced Solid Tumors (ECHO-203) | NCT02318277 | Solid Tumors Head and Neck C... Lung Cancer UC (Urothelial ... | MEDI4736 INCB024360 | 18 Years - | Incyte Corporation | |
| Evaluate the Efficacy of MEDI4736 in Immunological Subsets of Advanced Colorectal Cancer | NCT02227667 | Advanced Colore... | MEDI4736 | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Durvalumab And Radiation Therapy Followed by Adjuvant Durvalumab in Patients With Urothelial Cancer (T2-4 N0-2 M0) of the Bladder | NCT02891161 | Urothelial Canc... | durvalumab Radiation Thera... | 18 Years - | Big Ten Cancer Research Consortium | |
| A Study of Durvalumab (Anti-PDL1) Plus Radiation Therapy for the Treatment of Solitary Bone Plasmacytoma | NCT03196401 | Solitary Bone P... | Durvalumab Radiation thera... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Study of Durvalumab (MEDI4736) (Anti-PD-L1) and Trametinib (MEKi) in MSS Metastatic Colon Cancer | NCT03428126 | Malignant Neopl... Colorectal Canc... Colon Cancer | Durvalumab Trametinib | 18 Years - | M.D. Anderson Cancer Center | |
| Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer | NCT02546661 | Muscle Invasive... | AZD4547 MEDI4736 Olaparib AZD1775 Vistusertib AZD9150 Selumetinib | 18 Years - 130 Years | AstraZeneca | |
| Planning Treatment for Oesophago-gastric Cancer: a Maintenance Therapy Trial | NCT02678182 | Adenocarcinoma ... Adenocarcinoma ... Adenocarcinoma ... | Capecitabine MEDI4736 Trastuzumab Rucaparib Ramucirumab | 18 Years - | Royal Marsden NHS Foundation Trust |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
